PROCEPT BioRobotics (NASDAQ:PRCT) and Rockwell Medical (NASDAQ:RMTI) Head-To-Head Analysis

PROCEPT BioRobotics (NASDAQ:PRCT) and Rockwell Medical (NASDAQ:RMTI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Volatility & Risk

PROCEPT BioRobotics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for PROCEPT BioRobotics and Rockwell Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2	9	3	2	2.31
Rockwell Medical	2	0	1	0	1.67

PROCEPT BioRobotics presently has a consensus target price of $25.50, suggesting a potential upside of 39.50%. Rockwell Medical has a consensus target price of $20.00, suggesting a potential upside of 167.02%. Given Rockwell Medical’s higher probable upside, analysts clearly believe Rockwell Medical is more favorable than PROCEPT BioRobotics.

Institutional & Insider Ownership

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 4.6% of Rockwell Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares PROCEPT BioRobotics and Rockwell Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05 million	3.40	-$95.57 million	($1.94)	-9.42
Rockwell Medical	$69.26 million	0.44	-$5.31 million	($1.34)	-5.59

Rockwell Medical has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Rockwell Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PROCEPT BioRobotics and Rockwell Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
Rockwell Medical	-7.33%	-14.03%	-8.90%

Summary

Rockwell Medical beats PROCEPT BioRobotics on 8 of the 14 factors compared between the two stocks.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About Rockwell Medical

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.